CENTANY Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Centany patents expire, and when can generic versions of Centany launch?
Centany is a drug marketed by Padagis Us and is included in one NDA.
The generic ingredient in CENTANY is mupirocin. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the mupirocin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Centany
A generic version of CENTANY was approved as mupirocin by PADAGIS ISRAEL on November 7th, 2003.
Summary for CENTANY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 83 |
| Clinical Trials: | 2 |
| Patent Applications: | 6,098 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in CENTANY? | CENTANY excipients list |
| DailyMed Link: | CENTANY at DailyMed |
Recent Clinical Trials for CENTANY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of North Carolina, Chapel Hill | Phase 2 |
| University of Michigan | Phase 2 |
| Indiana University | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for CENTANY
US Patents and Regulatory Information for CENTANY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Padagis Us | CENTANY | mupirocin | OINTMENT;TOPICAL | 050788-001 | Dec 4, 2002 | BX | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CENTANY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Padagis Us | CENTANY | mupirocin | OINTMENT;TOPICAL | 050788-001 | Dec 4, 2002 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CENTANY
See the table below for patents covering CENTANY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 123143 | PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN | See Plans and Pricing |
| Canada | 2259764 | COMPOSITIONS PHARMACEUTIQUES RENFERMANT DE LA MUPIROCINE (PHARMACEUTICAL COMPOSITIONS CONTAINING MUPIROCIN) | See Plans and Pricing |
| Spain | 2165723 | See Plans and Pricing | |
| Germany | 69900561 | See Plans and Pricing | |
| European Patent Office | 0933081 | Compositions pharmaceutiques contenant mupirocine (Pharmaceutical compositions containing mupirocin) | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
